Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1800795
rs1800795
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 GeneticVariation BEFREE Most associations varied by recent aspirin/NSAID use: IL6 rs1800796 and rs1800795 polymorphisms were associated inversely with tumor mutations in the presence of aspirin/NSAIDs; POMC significantly reduced risk of Ki-ras-mutated tumors when aspirin/NSAIDs were not used; the TCF7L2 rs7903146 was associated with reduced risk of Ki-ras-mutated tumors in the presence of aspirin and increased risk in the absence of aspirin. 18992263

2009

dbSNP: rs1800795
rs1800795
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 GeneticVariation BEFREE There were no significant relationships between rs1800795 status and any patient or tumor characteristics, including estrogen receptor status. 28732081

2017

dbSNP: rs1800795
rs1800795
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 GeneticVariation BEFREE We assessed how these tumor markers were associated with use of anti-inflammatory drugs, polymorphisms in the IL6 genes (rs1800795 and rs1800796) and dietary antioxidants. 19452524

2009

dbSNP: rs1800795
rs1800795
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 GeneticVariation BEFREE The rs1800795 polymorphism in the promoter of the gene IL-6 can affect the transcription and expression of the gene, becoming a common target in association studies on tumors. 28296724

2017

dbSNP: rs1800795
rs1800795
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 GeneticVariation BEFREE Associations between potentially functional IL6 (rs2069837 and rs1800795) and STAT3 (rs744166 and rs4796793) SNPs and clinical outcomes [progression-free survival (PFS), overall survival, and tumor response rate] were evaluated in mCRC patients receiving first-line FOLFIRI plus bevacizumab in two randomized phase III trials: TRIBE (n = 223, training cohort) and FIRE-3 (n = 288, validation cohort). 26839145

2016